Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid ...

Compass Pathways’ stock has crashed by nearly 50% despite the company announcing its Phase III trial of psilocybin had met ...

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.

Findings showed COMP360 psilocybin statistically significantly reduced symptom severity compared with placebo, as measured by MADRS.

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

An Iowa lawmaker who pushed for a bill allowing the medicinal use of psilocybin is supporting of Gov. Kim Reynold’s veto of a ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 ...